133 related articles for article (PubMed ID: 38922003)
21. Evaluation of the safety of a combination of oral administration of phenylbutazone and firocoxib in horses.
Kivett L; Taintor J; Wright J
J Vet Pharmacol Ther; 2014 Aug; 37(4):413-6. PubMed ID: 24354928
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and bioavailability of oral firocoxib in adult, mixed-breed goats.
Stuart AK; KuKanich B; Caixeta LS; Coetzee JF; Barrell EA
J Vet Pharmacol Ther; 2019 Nov; 42(6):640-646. PubMed ID: 31435966
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of firocoxib after administration of multiple consecutive daily doses to horses.
Letendre LT; Tessman RK; McClure SR; Kvaternick VJ; Fischer JB; Hanson PD
Am J Vet Res; 2008 Nov; 69(11):1399-405. PubMed ID: 18980421
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of selective and non-selective cyclooxygenase inhibitors on fecal microbiota in adult horses.
Whitfield-Cargile CM; Chamoun-Emanuelli AM; Cohen ND; Richardson LM; Ajami NJ; Dockery HJ
PLoS One; 2018; 13(8):e0202527. PubMed ID: 30138339
[TBL] [Abstract][Full Text] [Related]
25. Detection and pharmacokinetics of three formulations of firocoxib following multiple administrations to horses.
Knych HK; Stanley SD; Arthur RM; Mitchell MM
Equine Vet J; 2014 Nov; 46(6):734-8. PubMed ID: 24393414
[TBL] [Abstract][Full Text] [Related]
26. Clinical effectiveness and safety of a new NSAID, firocoxib: a 1,000 dog study.
Ryan WG; Moldave K; Carithers D
Vet Ther; 2006; 7(2):119-26. PubMed ID: 16871494
[TBL] [Abstract][Full Text] [Related]
27. Prolonged administration of oral phenylbutazone and firocoxib in horses has no impact on selected cytokine and growth factor concentrations in platelet-rich plasma and autologous protein solution.
Brown KA; Gregorio EN; Barot D; Usimaki A; Linardi RL; Missanelli JR; You Y; Robinson MA; Ortved KF
Am J Vet Res; 2024 Jun; ():1-8. PubMed ID: 38889765
[TBL] [Abstract][Full Text] [Related]
28. Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis.
Doucet MY; Bertone AL; Hendrickson D; Hughes F; Macallister C; McClure S; Reinemeyer C; Rossier Y; Sifferman R; Vrins AA; White G; Kunkle B; Alva R; Romano D; Hanson PD
J Am Vet Med Assoc; 2008 Jan; 232(1):91-7. PubMed ID: 18167116
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological Regulation in the USA and Pharmacokinetics Parameters of Firocoxib, a Highly Selective Cox-2, by Pain Management in Horses.
Rangel-Nava A; Ramírez-Uribe JM; Recillas-Morales S; Ibancovichi-Camarillo JA; Venebra-Muñoz A; Sánchez-Aparicio P
J Equine Vet Sci; 2019 Jun; 77():36-42. PubMed ID: 31133314
[TBL] [Abstract][Full Text] [Related]
30. Update on the use of cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs in horses.
Ziegler A; Fogle C; Blikslager A
J Am Vet Med Assoc; 2017 Jun; 250(11):1271-1274. PubMed ID: 28509650
[TBL] [Abstract][Full Text] [Related]
31. SINGLE-DOSE, MULTIPLE-DOSE, AND THERAPEUTIC DRUG MONITORING PHARMACOKINETICS OF FIROCOXIB IN ASIAN ELEPHANTS (
Kottwitz J; Bechert U; Cruz-Espindola C; Christensen JM; Boothe D
J Zoo Wildl Med; 2024 Mar; 55(1):73-85. PubMed ID: 38453490
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and safety of firocoxib after oral administration of repeated consecutive doses to neonatal foals.
Hovanessian N; Davis JL; McKenzie HC; Hodgson JL; Hodgson DR; Crisman MV
J Vet Pharmacol Ther; 2014 Jun; 37(3):243-51. PubMed ID: 24749691
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses.
Holland B; Fogle C; Blikslager AT; Curling A; Barlow BM; Schirmer J; Davis JL
J Vet Pharmacol Ther; 2015 Jun; 38(3):249-56. PubMed ID: 25378135
[TBL] [Abstract][Full Text] [Related]
34. Effects of firocoxib, meloxicam, and tepoxalin administration on eicosanoid production in target tissues of healthy cats.
Goodman LA; Torres BT; Reynolds LR; Budsberg SC
Am J Vet Res; 2010 Sep; 71(9):1067-73. PubMed ID: 20807147
[TBL] [Abstract][Full Text] [Related]
35. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia.
McCann ME; Rickes EL; Hora DF; Cunningham PK; Zhang D; Brideau C; Black WC; Hickey GJ
Am J Vet Res; 2005 Jul; 66(7):1278-84. PubMed ID: 16111170
[TBL] [Abstract][Full Text] [Related]
36. Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
Jones P; Dalziel SR; Lamdin R; Miles-Chan JL; Frampton C
Cochrane Database Syst Rev; 2015 Jul; (7):CD007789. PubMed ID: 26130144
[TBL] [Abstract][Full Text] [Related]
37. The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis.
Vijarnsorn M; Kwananocha I; Kashemsant N; Jarudecha T; Lekcharoensuk C; Beale B; Peirone B; Lascelles BDX
BMC Vet Res; 2019 Oct; 15(1):349. PubMed ID: 31623621
[TBL] [Abstract][Full Text] [Related]
38. Oral non-steroidal anti-inflammatory drugs (single dose) for perineal pain in the early postpartum period.
Wuytack F; Smith V; Cleary BJ
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011352. PubMed ID: 27412362
[TBL] [Abstract][Full Text] [Related]
39. The effectiveness of low-dose of eCG in timed AI Nelore (Bos indicus) heifers.
Neto ARF; Souza DFC; Campos RA; Albertini S; Bastos MR; Freitas BG; Colli MHA; Elliff FM; Sales JNS; Baruselli PS
Reprod Domest Anim; 2024 Mar; 59(3):e14553. PubMed ID: 38501644
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and tissue concentrations of firocoxib in sows following oral administration.
Kleinhenz MD; Odland C; Williams TE; Zhang Y; Fitzgerald AH; Sidhu PK; Wulf LW; Coetzee JF
J Vet Pharmacol Ther; 2020 Sep; 43(5):491-498. PubMed ID: 32266983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
